for retails approx 99972 forms of 16 shares each so if retailers apply like LT INfotech 11 Lakh forms then allotment with be 1:11 Gmp is 350 per share * 16 share = Rs 5600 u can gain. so applied for 11 forms *14336 =157696 investment max gain approx 5600 if u got 1 lot still a risk if u not allot any share no gain other thing is if gmp is down like LT Infotech then gain will very less
Key take-aways Advance enzymes technologies • Operating since 1958, started with papaya enzyme • Promoter having more than three decades of experience in enzyme technology and one of them is enzymologist • Focusing on nutraceutical segment in USA • Wanted to stick with Human and Animal nutrition instead of industrial enzymes producer • It''s complete package of enzyme play i.e. having backward and forward integration both which also make them unique as per business model. Only few operates in similar way • Currently operating at 45% capacity with better margin than its peer who enjoys leadership globally • High entry barrier business because it requires lot of time on R&D and time consuming process to build any enzyme molecules • Upcoming opportunities in pharmaceutical companies, like Pharma company looking to shift from synthetic process to enzymatic process because it is a green technology • India is having 2% enzyme consumption and there is huge gap between per capita consumption of developed nations and India • Company has huge capacity built in because nature of business and kind of process needed to build particular enzyme (first you have to develop a enzyme and then you have to market) • US plant is only to serve local client and provide customize solution not for bulk production • Company has recalled its product in FY 14 as they were not able to pay interest and ultimately defaulted on payment. But now they paid there most of debt. Debt equity now 0.36x FY16 and going down further • Company sell products in US under food regulations not under drug regulations which is comparatively more stringent (Law only look whether it’s safe to consume or not) • Market share of 20% in India. Ranked top 15 and aim to be in top 10
Peers trade at 35x of FY16 EPS and Advance available at 25x So one can look to subscribe